The China lung cancer screening market size is anticipated to reach USD 1.04 billion by 2030 and is projected to grow at a CAGR of 11.09% during the forecast period. This growth trajectory is driven by several pivotal factors, notably the high incidence and mortality rates of lung cancer in China. The National Library of Medicine reports that lung cancer was the most prevalent cancer in China in 2022, with approximately 1,060,600 new cases, outpacing colorectal cancer, which had 517,100 cases.
The high burden of lung cancer underscores the critical need for effective screening solutions. Advanced screening technologies, such as low-dose computed tomography (CT) scans, have revolutionized early detection, significantly improving survival rates by identifying cancers at earlier, more treatable stages. In addition, government initiatives, including the Healthy China 2030 plan, have expanded access to screening services, especially in rural and underserved areas, enhancing early detection and treatment capabilities.
Moreover, technological advancements in screening methodologies have significantly contributed to market growth. Low-dose computed tomography (LDCT) has emerged as a key tool in early lung cancer detection, offering superior sensitivity compared to traditional imaging techniques. LDCT’s ability to detect lung cancer at an early stage has been instrumental in improving patient outcomes and reducing treatment costs. The increasing availability and affordability of advanced imaging technologies have made them more accessible to a broader population, further driving market expansion.
The market's growth is also supported by innovations in diagnostic tools, such as AI-enhanced imaging technologies, which improve the accuracy and efficiency of screenings. These advancements contribute to the broader adoption of screening programs and increased market demand. For instance, in March 2024, Alibaba Group's research division, DAMO Academy, introduced a new cancer screening tool in hospitals across China. This innovative AI-powered diagnostic tool, now operational in two hospitals in Zhejiang province, significantly accelerates the detection of various cancers. The device can analyze CT scans in under three minutes-one-third of the time required for manual examination by a physician. This advancement enhances both the speed and cost-effectiveness of cancer diagnosis, marking a significant leap forward in cancer screening technology.
This product will be delivered within 1-3 business days.
The high burden of lung cancer underscores the critical need for effective screening solutions. Advanced screening technologies, such as low-dose computed tomography (CT) scans, have revolutionized early detection, significantly improving survival rates by identifying cancers at earlier, more treatable stages. In addition, government initiatives, including the Healthy China 2030 plan, have expanded access to screening services, especially in rural and underserved areas, enhancing early detection and treatment capabilities.
Moreover, technological advancements in screening methodologies have significantly contributed to market growth. Low-dose computed tomography (LDCT) has emerged as a key tool in early lung cancer detection, offering superior sensitivity compared to traditional imaging techniques. LDCT’s ability to detect lung cancer at an early stage has been instrumental in improving patient outcomes and reducing treatment costs. The increasing availability and affordability of advanced imaging technologies have made them more accessible to a broader population, further driving market expansion.
The market's growth is also supported by innovations in diagnostic tools, such as AI-enhanced imaging technologies, which improve the accuracy and efficiency of screenings. These advancements contribute to the broader adoption of screening programs and increased market demand. For instance, in March 2024, Alibaba Group's research division, DAMO Academy, introduced a new cancer screening tool in hospitals across China. This innovative AI-powered diagnostic tool, now operational in two hospitals in Zhejiang province, significantly accelerates the detection of various cancers. The device can analyze CT scans in under three minutes-one-third of the time required for manual examination by a physician. This advancement enhances both the speed and cost-effectiveness of cancer diagnosis, marking a significant leap forward in cancer screening technology.
China Lung Cancer Screening Market Report Highlights
- Non-small cell lung cancer held the largest share of 81.29% in 2023, driven notably by the high prevalence, advancements in diagnostic technology, supportive government policies, and improvements in healthcare infrastructure
- On the basis of diagnosis, Low Dose Spiral CT (LDCT) Scan held the largest share of more than 70.0% in 2023 and it is also expected to grow at the fastest CAGR over the forecast period
- In 2023, diagnostic centers commanded the largest market share of 45.36% in the lung cancer screening sector. This dominance is attributed to their utilization of advanced imaging technologies, which provide high-resolution and accurate diagnostic capabilities
The leading players in the China Lung Cancer Screening market include:
- Biodesix
- DELFI Diagnostics, Inc.
- GE HealthCare
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- Siemens Healthineers AG
- Koninklijke Philips N.V.
- CANON MEDICAL SYSTEMS CORPORATION
- Medtronic
- Shanghai United Imaging Healthcare Co., LTD
- Freenome Holdings, Inc.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. China Lung Cancer Screening Market Variables, Trends & Scope
Chapter 4. China Lung Cancer Screening Market: Cancer Estimates & Trend Analysis
Chapter 5. China Lung Cancer Screening Market: Diagnosis Estimates & Trend Analysis
Chapter 6. China Lung Cancer Screening Market: End Use Estimates & Trend Analysis
Chapter 7. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The leading players in the China Lung Cancer Screening market include:- Biodesix
- DELFI Diagnostics, Inc.
- GE HealthCare
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- Siemens Healthineers AG
- Koninklijke Philips N.V.
- CANON MEDICAL SYSTEMS CORPORATION
- Medtronic
- Shanghai United Imaging Healthcare Co., LTD
- Freenome Holdings, Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 160 |
| Published | September 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 505.17 Million |
| Forecasted Market Value ( USD | $ 1040 Million |
| Compound Annual Growth Rate | 11.0% |
| Regions Covered | China |
| No. of Companies Mentioned | 11 |
